Attovia Therapeutics, Inc. in brief
Attovia Therapeutics, Inc. is a listed company in the Biotechnology industry, based in San Carlos, California, USA. Its shares trade under the symbol ATTO (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
Attovia Therapeutics, Inc. timeline
- 2025
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2026
- 🔔Initial public offeringFinal prospectus filed with the SEC on 5 August 2026; shares registered for exchange trading on 29 July 2026.
Events of Attovia Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
Not enough history yet.
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-22M.
SEC filings
- Nov 9, 20268-KCurrent reportResults of operations · Other events
- Nov 9, 202610-QQuarterly report · period to Sep 2026
- Sep 2, 202610-QQuarterly report · period to Jun 2026
- Sep 2, 20268-KCurrent reportResults of operations
- Aug 6, 20268-KCurrent reportBylaws amended
- Aug 5, 2026424B4IPO prospectus
- Aug 4, 2026S-1/AIPO registration (amended)
- Jul 29, 2026S-1/AIPO registration (amended)
- Jul 14, 2026S-1IPO registration
Official filings of Attovia Therapeutics, Inc. with the US Securities and Exchange Commission.
Balance sheet
- Total assets
- $166 M
- Total liabilities
- $15 M
- Total equity
- $-107 M
As of December-2025
Top 64 institutional investors in Attovia Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 7,046,271 | New | 15.44% | $121 M | Nov 16, 2026 |
| 2 | Goldman Sachs Group Inc | 5,391,772 | New | 11.81% | $92 M | Nov 16, 2026 |
| 3 | venBio Partners LLC | 4,181,366 | New | 9.16% | $72 M | Nov 16, 2026 |
| 4 | Deep Track Capital, LP | 3,207,138 | New | 7.03% | $55 M | Nov 16, 2026 |
| 5 | EcoR1 Capital, LLC | 2,024,010 | New | 4.43% | $35 M | Nov 16, 2026 |
| 6 | Nextech Invest Ltd. | 1,835,139 | New | 4.02% | $31 M | Nov 16, 2026 |
| 7 | Cormorant Asset Management, LP | 1,788,815 | New | 3.92% | $31 M | Nov 16, 2026 |
| 8 | Redmile Group, LLC | 1,163,587 | New | 2.55% | $20 M | Nov 16, 2026 |
| 9 | Commodore Capital LP | 1,160,000 | New | 2.54% | $20 M | Nov 16, 2026 |
| 10 | Sanofi | 1,082,855 | New | 2.37% | $19 M | Nov 5, 2026 |
| 11 | Janus Henderson Group Ltd. | 1,000,000 | — | 2.19% | $17 M | Nov 16, 2026 |
| 12 | Marshall Wace, LLP | 898,980 | New | 1.97% | $15 M | Nov 13, 2026 |
| 13 | Vanguard Capital Management LLC | 782,012 | New | 1.71% | $13 M | Nov 13, 2026 |
| 14 | Federated Hermes, Inc. | 700,000 | New | 1.53% | $12 M | Nov 12, 2026 |
| 15 | Woodline Partners LP | 686,746 | New | 1.50% | $12 M | Nov 16, 2026 |
| 16 | Nantahala Capital Management, LLC | 561,180 | New | 1.23% | $10 M | Nov 13, 2026 |
| 17 | Adage Capital Partners GP, L.L.C. | 500,000 | New | 1.10% | $9 M | Nov 16, 2026 |
| 18 | Millennium Management LLC | 476,261 | New | 1.04% | $8 M | Nov 16, 2026 |
| 19 | Citadel Advisors LLC | 466,773 | New | 1.02% | $8 M | Nov 16, 2026 |
| 20 | Balyasny Asset Management L.P. | 459,297 | New | 1.01% | $8 M | Nov 16, 2026 |
| 21 | Integral Health Asset Management, LLC | 450,000 | New | 0.99% | $8 M | Nov 16, 2026 |
| 22 | Blackstone Inc. | 339,920 | New | 0.74% | $6 M | Nov 16, 2026 |
| 23 | FMR LLC | 323,669 | New | 0.71% | $6 M | Nov 10, 2026 |
| 24 | Vivo Capital, LLC | 300,000 | New | 0.66% | $5 M | Nov 13, 2026 |
| 25 | BlackRock, Inc. | 265,397 | New | 0.58% | $5 M | Nov 13, 2026 |
Show all 64: investors 26 to 64
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Spruce Street Capital LP | 228,295 | New | 0.50% | $4 M | Nov 13, 2026 |
| 27 | Braidwell LP | 225,000 | New | 0.49% | $4 M | Nov 16, 2026 |
| 28 | Geode Capital Management, LLC | 206,176 | New | 0.45% | $4 M | Nov 6, 2026 |
| 29 | Boxer Capital Management, LLC | 200,000 | New | 0.44% | $3 M | Nov 16, 2026 |
| 30 | Kalehua Capital Management LLC | 200,000 | New | 0.44% | $3 M | Nov 13, 2026 |
| 31 | UBS Group AG | 183,751 | New | 0.40% | $3 M | Nov 10, 2026 |
| 32 | Jones Hill Capital LP | 182,295 | New | 0.40% | $3 M | Nov 13, 2026 |
| 33 | Point72 Asset Management, L.P. | 180,664 | New | 0.40% | $3 M | Nov 16, 2026 |
| 34 | Stempoint Capital LP | 138,200 | New | 0.30% | $2 M | Nov 16, 2026 |
| 35 | Cantor Fitzgerald, L. P. | 133,959 | New | 0.29% | $2 M | Nov 16, 2026 |
| 36 | Burkehill Global Management, LP | 120,000 | New | 0.26% | $2 M | Nov 16, 2026 |
| 37 | Freestone Grove Partners LP | 120,000 | New | 0.26% | $2 M | Nov 16, 2026 |
| 38 | Charles Schwab Investment Management Inc | 114,952 | New | 0.25% | $2 M | Nov 16, 2026 |
| 39 | Vanguard Fiduciary Trust Co | 109,177 | New | 0.24% | $2 M | Nov 13, 2026 |
| 40 | Ghisallo Capital Management LLC | 105,000 | New | 0.23% | $2 M | Nov 16, 2026 |
| 41 | Seven Grand Managers, LLC | 90,000 | New | 0.20% | $2 M | Nov 16, 2026 |
| 42 | Two Sigma Investments, LP | 54,828 | New | 0.12% | $1 M | Nov 16, 2026 |
| 43 | Squarepoint Ops LLC | 42,725 | New | 0.09% | $1 M | Nov 9, 2026 |
| 44 | LMR Partners LLP | 40,000 | New | 0.09% | $1 M | Nov 16, 2026 |
| 45 | Northern Trust Corp | 39,287 | New | 0.09% | $1 M | Nov 16, 2026 |
| 46 | Morgan Stanley | 38,451 | New | 0.08% | $1 M | Nov 13, 2026 |
| 47 | HRT Financial LP | 30,868 | New | 0.07% | $1 M | Nov 13, 2026 |
| 48 | State Street Corp | 24,250 | New | 0.05% | $0 M | Nov 12, 2026 |
| 49 | Schonfeld Strategic Advisors LLC | 22,243 | New | 0.05% | $0 M | Nov 16, 2026 |
| 50 | Vanguard Portfolio Management LLC | 20,495 | New | 0.04% | $0 M | Nov 13, 2026 |
| 51 | Jump Financial, LLC | 16,594 | New | 0.04% | $0 M | Nov 13, 2026 |
| 52 | Walleye Capital LLC | 15,107 | New | 0.03% | $0 M | Nov 13, 2026 |
| 53 | Legal & General Group Plc | 15,000 | New | 0.03% | $0 M | Nov 16, 2026 |
| 54 | Landscape Capital Management, L.L.C. | 14,806 | New | 0.03% | $0 M | Nov 10, 2026 |
| 55 | ExodusPoint Capital Management, LP | 13,576 | New | 0.03% | $0 M | Nov 16, 2026 |
| 56 | D. E. Shaw & Co., Inc. | 10,058 | New | 0.02% | $0 M | Nov 16, 2026 |
| 57 | Soleus Capital Management, L.P. | 10,000 | New | 0.02% | $0 M | Nov 16, 2026 |
| 58 | Diadema Partners LP | 9,700 | New | 0.02% | $0 M | Nov 16, 2026 |
| 59 | Aster Capital Management (DIFC) Ltd | 7,774 | New | 0.02% | $0 M | Nov 12, 2026 |
| 60 | Vanguard Global Advisers, LLC | 6,602 | New | 0.01% | $0 M | Nov 13, 2026 |
| 61 | Allworth Financial LP | 4,000 | New | 0.01% | $0 M | Nov 17, 2026 |
| 62 | Persistent Asset Partners Ltd | 2,465 | New | 0.01% | $0 M | Nov 13, 2026 |
| 63 | Citigroup Inc | 1,237 | New | 0.00% | $0 M | Nov 4, 2026 |
| 64 | Osaic Holdings, Inc. | 180 | New | 0.00% | $0 M | Nov 12, 2026 |
Insider trading at Attovia Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Goldman Sachs Asset Management, L.P.Former 10% Owner | Conversionindirect · amended | +1.96 M | — | — | 2.04 M | Form 4/A |
| filed | Colin WalshDirector | Conversionindirect · amended | +1.96 M | — | — | 2.04 M | Form 4/A |
| filed | Goldman Sachs Asset Management, L.P.Former 10% Owner | Conversionindirect · amended | +478,498 | — | — | 2.52 M | Form 4/A |
| filed | Colin WalshDirector | Conversionindirect · amended | +478,498 | — | — | 2.52 M | Form 4/A |
| filed | Goldman Sachs Asset Management, L.P.Former 10% Owner | Buyindirect · amended | +500,000 | $17.00 | — | 3.02 M | Form 4/A |
| filed | Colin WalshDirector | Buyindirect · amended | +500,000 | $17.00 | — | 3.02 M | Form 4/A |
| filed | Goldman Sachs & Co. LLCFormer 10% Owner | Conversionindirect | +1.96 M | — | — | 2.04 M | Form 4 |
| filed | Colin WalshDirector | Conversionindirect | +1.96 M | — | — | 2.04 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Attovia Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
IPO: priced at $17.00, raising $289M · IPO calendar
Fails to deliver
- : 222 shares at $15.00
- : 461 shares at $14.50
- : 391 shares at $13.73
- : 3,979 shares at $14.78
- : 180 shares at $14.96
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Attovia Therapeutics, Inc. scorecard#
Passes 1 of the 1 checks that could be worked out. Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growthnot known
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitabilitynot known
- –Profitable in the newest yearNo net income on file.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 1
- ✓Short-term assets cover short-term liabilities14.2×Current ratio 14.20 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Events at Attovia Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Bylaws or fiscal year changed 1 · Results announced 2
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Attovia Therapeutics, Inc.🇺🇸 | — | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 15, 2026
Figures from value.today research, SEC filing; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Attovia Therapeutics, Inc.? Verify and update this profile — free
Show Attovia Therapeutics, Inc.'s ranking on your website Get the badge
The badge updates itself as the ranking changes.